Skip to main content
Evidence Snapshot

Adenosine receptor A3

CHEMBL256 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:38:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL256
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adenosine receptor A3 as ChEMBL target CHEMBL256, mapped to UniProt P0DMS8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Adenosine receptor A3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL256
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P0DMS8
Adenosine receptor A3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Adenosine receptor A3 matters

As of 2026-09-13

Adenosine receptor A3 is reviewed as Adenosine receptor A3 (UniProt P0DMS8); Adenosine receptor A3 shows late clinical disease relevance led by dry eye syndrome. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 82 approved drugs, 10791 compounds, and 1434 assays, with lead potency reaching pChEMBL 11.0.

Disease context
dry eye syndrome

Adenosine receptor A3 shows late clinical disease relevance led by dry eye syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PICLIDENOSON.

Start review with dry eye syndrome because it currently carries late clinical support. Linked drugs include PICLIDENOSON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 82 approved drugs, 10791 compounds, and 1434 assays for this target. The dominant activity type is KI. CHEMBL332091 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL332091 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
82 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Adenosine receptor A3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P0DMS8, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why dry eye syndrome is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

10791
Total Compounds
1434
Total Assays
82
Approved Drugs
IC50: 1899.0, KI: 7914.0, EC50: 498.0, KD: 96.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL332091
 11.0 Ki —
No preferred name
CHEMBL118923
 11.0 Ki —
No preferred name
CHEMBL1771603
 11.0 Ki —
No preferred name
CHEMBL119709
 10.8 IC50 —
No preferred name
CHEMBL5558289
 10.8 EC50 —

Approved Drugs

Structure Compound First Approval
MONTELUKAST
CHEMBL787
 1998
ZAFIRLUKAST
CHEMBL603
 1996
FELODIPINE
CHEMBL1480
 1991
ADENOSINE
CHEMBL477
 1989
OXICONAZOLE
CHEMBL1262
 1988
HALOPROGIN
CHEMBL1289
 1982
THEOPHYLLINE
CHEMBL1355736
 1976
DISULFIRAM
CHEMBL964
 1951
HEXACHLOROPHENE
CHEMBL496
 1949
BITHIONOL
CHEMBL290106
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:38:07Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL256